Sales of Teva's multiple sclerosis drug, Copaxone, are still growing--at least for now. The Israeli company's top-seller, whose patent is currently the subject of a Supreme Court appeal, ticked up 5% to reach $1.1 billion in Q3 sales.
Bayer is already coasting along sales-wise, with some powerhouse new drugs helping it beat analysts' third-quarter forecasts. And those sales will only keep on growing, the company said Thursday as it raised its revenue and profit forecasts.
For the now-former chief of Sanofi, Chris Viehbacher, there's plenty of money for a cushion, but it won't be nearly as plump as the packages granted to his counterparts in the U.S.
Abbott has made its move on a trio of med tech startups focused on cardiovascular catheterization. It is buying electrophysiology startup Topera for $250 million plus undisclosed milestones and has secured the right to purchase Advanced Cardiac Therapeutics, which has a novel ablation catheter. Plus, Abbott Ventures participated in a venture round for VytronUS.
Mousera, a healthcare startup focused on bringing current systems research up to speed with modern technology, raised $8.8 million from 9 investors.
Gilead Sciences is charting eye-popping sales for blockbuster Sovaldi and chalking up a key regulatory approval for its new hep C combo pill, Harvoni. But the company's third-quarter earnings fell short of analysts' estimates in light of a hefty Obamacare fee and lower-than-expected revenue for its top-selling hep C drug.
Sanofi's animal health division, Merial, provided a rare bright spot in the company's third-quarter earnings report--but it wasn't quite bright enough to save CEO Chris Viehbacher's job. On Wednesday, just after announcing so-so earnings that triggered a massive selloff of Sanofi's stock, the company's board said it has "decided unanimously to remove" Viehbacher.
Valeant's hostile bid for Allergan may soon be on the rise. But after posting strong Q3 results earlier this week, some analysts say Allergan's value is, too.
Novartis' third-quarter profit may have gotten a large boost from the sale of its Idenix stake to Merck this summer, with cost cuts kicking in, too. But when it comes to top-line results that topped analysts' forecasts, the company has its own hot sellers to thank.
Alere continued down the path of deleveraging and refocusing on its core competency in diagnostics with the sale of its Alere Health unit to Optum, a part of the insurance company UnitedHealth Group for $600 million.